IL6 and neuromyelitis optica: Recently, two case series demonstrated that treatment with anti-IL-6R mAb has positive effects in neuromyelitis optica spectrum disorders in humans, further underlining the relevance of IL-6 in pathogenesis of CNS demyelinating disorders [50].